Document is current

Article History

Received: 22 July 2020

Accepted: 13 October 2020

First Online: 26 October 2020

Compliance with ethical standards

:

: Ellingson—Advisory Board—Hoffman La-Roche; Siemens; Nativis; Medicenna; MedQIA; Bristol Meyers Squibb; Imaging Endpoints; Agios. Paid Consultant—Nativis; MedQIA; Siemens; Hoffman La-Roche; Imaging Endpoints; Medicenna; Agios. Grant Funding—Hoffman La-Roche; Siemens; Agios; Janssen. Dr. Ellingson also holds a patent on this technology (US Patent #15/577,664; International PCT/US2016/034886).Cloughesy—Advisory Board– Roche/Genentech, Amgen, Tocagen, NewGen, LPath, Proximagen, Celgene, Vascular Biogenics Ltd, Insys, Agios, Cortice Bioscience, Pfizer, Human Longevity, BMS, Merck, Notable Lab, MedQIA.Nathanson— Co-Founder of Katmai Pharmaceuticals, Consultant of Katmai Pharmaceuticals, Co-Founder of Trethera Corporation, Shareholder in Sofie Biosciences.Oughourlian—None related to this study.Yao—None related to this study.Hagiwara—None related to this study.Raymond—None related to this study.Pope—None related to this study.Salamon—None related to this study.Lai—None related to this study.Ji—None related to this study.Nghiemphu—None related to this study.Liau—None related to this study.

: All procedures performed in reports involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all participants before evaluation.